DMAC News and Press, DiaMedica Therapeutics Inc. From 03/06/23

DiaMedica Continues Building Out Board Of Directors With Key Biopharma Industry Leaders DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, announced today the app...

DiaMedica Therapeutics press release ( NASDAQ: DMAC ): Q3 GAAP EPS of -$0.12 beats by $0.03 . Total cash, cash equivalents and investments of $36.1M. For further details see: DiaMedica Therapeutics GAAP EPS of -$0.12 beats by $0.03

Company to Conduct In-Use Study to Address FDA Latest Information Request Cash Runway Into Q4 2024 DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological d...

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that Rick Pauls, its President and CEO will be participating in the 13th Annual Craig-Hallum Alph...

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that Rick Pauls, its President and CEO, will present a corporate overview at the Credit Suisse 31...

DiaMedica Therapeutics ( NASDAQ: DMAC ) stock slid 17% after hours on Wednesday as the firm said the U.S. FDA is maintaining its clinical hold on its ReMEDy2 phase 2/3 trial evaluating DM199 to treat acute ischemic stroke ( AIS ). The regulator said it needs...

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, announced today that the Company has received further guidance from the U.S. Food and Drug Administration (FDA) r...

Leadership Team Continues to Expand with Addition of Key Leader in Clinical Operations DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, announced toda...

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that Rick Pauls, its President and CEO will be participating at Lake Street Capital Market’...

DiaMedica Therapeutics Inc. (DMAC) Q2 2022 Earnings Conference Call August 11, 2022, 08:00 AM ET Company Participants Rick Pauls - President and Chief Executive Officer Kirsten Gruis - Chief Medical Officer Scott Kellen - Chief Financial Officer Conference ...